EMQN, a leading global business that provides quality assurance tools and service for laboratories that perform genetic testing and molecular diagnostics, has agreed a deal to take more than 5,000 sq ft on the third floor of Exchange Quay’s ICE building.
As a leader in its field, EMQN’s External Quality Assessment (EQA) accredited schemes seek to ensure the highest standards in clinical diagnostics test execution, accuracy, performance, interpretation, reliability and reporting. Trusted worldwide, EMQN’s EQA schemes are essential in delivering precise results critical to informed patient care and optimal clinical outcomes.
The deal will see the company’s 26-strong workforce relocating from Manchester’s Science Park on a 10 year lease to 5,212 sq ft at Exchange Quay. The recently refurbished building provides a number of collaborative work areas including dedicated social, meeting and bar space, as well as hireable meeting rooms and co-working zones and specifically designed wellbeing spaces to relax.
EMQN was spun out of the Manchester University NHS Foundation Trust (MFT) in June 2021 with 9 people and has since grown to a team of 26.
The initial driver for the move to Exchange Quay was around capacity, having outgrown its space at Manchester Science Park after 4 years based there. The amenity offer on campus was also a consideration to move, as well as the quality fit out of the space. The relocation will support the company’s growth plans to expand its capabilities further.
Les Lang, Director, Till AM said: “EMQN is an internationally-respected, UKAS-accredited provider of EQA services which delivers the highest quality molecular genetics testing certification, a vital component of clinical governance for its members. We are thrilled to welcome EMQN and It is testament to the high quality amenity offer we have at Exchange Quay, that has attracted such a market leading organisation to our growing business community.”
Simon Patton, CEO of EMQN said “As we embark on this exciting new chapter at EMQN, we are proud to reflect on our growth and reaffirm our unwavering commitment to supporting laboratories in delivering the highest standards in molecular pathology and genetic testing. Our new space in Exchange Quay will significantly enhance our capacity to provide innovative solutions, ensuring the utmost accuracy and reliability in clinical diagnostics on a global scale.”
James Dickinson, Director at Canning O’Neill, commented “Exchange Quay offers occupiers a prestigious, progressive office campus that not only provides a great location, with excellent road and public transport connections, it also provides further benefits in restaurant facilities, an on-site nursery, a post office, convenience store and gym. It is an exciting place to work which promotes a perfect work life balance through its high-quality office space and wellbeing provision.”
Agents on Exchange Quay are Canning O’Neill and Colliers. EMQN were represented by Stephen Woodall of Taylor Rose Solicitors.
